Eye - diabetic macular oedema
The PBS subsidises aflibercept, dexamethasone intravitreal implant and ranibizumab for patients with diabetic macular oedema (DMO).
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with aflibercept, dexamethasone intravitreal implant and ranibizumab under the National Health Act 1953, Section 85 for patients with DMO.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing aflibercept, dexamethasone intravitreal implant and ranibizumab.
Patients must be treated by an opthamologist or in consultation with an opthamologist to be eligible for PBS subsidised treatment with these medications.
Applications for initial treatment
Apply for authority approval to prescribe initial PBS subsidised aflibercept, dexamethasone intravitreal implant and ranibizumab to treat patients with DMO in writing and either:
All applications must include the completed:
- authority prescription form or forms
- Diabetic Macular Oedema Initial PBS authority application form
- relevant attachments.
If urgent, you can fax the first authority application to us on 1300 093 177. Our operating hours are Monday to Friday from 8 am to 5 pm AEST. Then the PBS Complex Drugs Programs Team will call you.
Applications for continuing treatment
Continuing authority applications to prescribe PBS subsidised aflibercept, dexamethasone intravitreal implant and ranibizumab to treat DMO can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Call the PBS Complex Drugs Programs enquiry line for more information.
Page last updated: 1 June 2020
This information was printed 6 July 2020 from https://www.servicesaustralia.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/eye-diabetic-macular-oedema. It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.servicesaustralia.gov.au/individuals/site-notices when using this material.